Ricardo Navarro, DO
Internal Medicine · Lake Wales, FLNPI 1346628971
Payments from drug & device makers
Across 420 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$808
- GSK$765
- Lilly USA, LLC$697
- AstraZeneca$628
- Amgen$589
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,64099%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $1,137 |
| Novo Nordisk | 47 | $808 |
| GSK | 44 | $765 |
| Lilly USA, LLC | 47 | $697 |
| AstraZeneca | 38 | $628 |
| Amgen(2 entities) | 38 | $589 |
| Bayer | 13 | $354 |
| Boehringer Ingelheim | 19 | $346 |
| Pfizer | 15 | $268 |
| Biohaven Pharmaceuticals, Inc. | 9 | $267 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $183 |
| Dexcom, Inc. | 9 | $174 |
| Abbott | 8 | $147 |
| Exact Sciences | 7 | $137 |
| Antares Pharma, Inc. | 8 | $134 |
| Esperion Therapeutics, Inc. | 7 | $134 |
| Radius Health, Inc. | 6 | $119 |
| Medtronic | 1 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $94 |
| Merck | 5 | $88 |
| Johnson & Johnson | 5 | $80 |
| Phadia US Inc. | 3 | $64 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Halozyme Inc | 2 | $35 |
| Lucid Diagnostics Inc. | 2 | $35 |
| Novartis | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Insulet Corporation | 1 | $21 |
| Tolmar, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Nevro Corp. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$120
- UBRELVY$120
- NURTEC ODT$107
- COREVALVE EVOLUT R$102
- Kerendia$100
How this compares
$7,699 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $234,693 |
| EliquisApixaban | 126 | $150,926 |
| JardianceEmpagliflozin | 96 | $146,459 |
| FarxigaDapagliflozin Propanediol | 51 | $68,176 |
| TrulicityDulaglutide | 33 | $65,346 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $59,114 |
| XareltoRivaroxaban | 50 | $51,277 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $44,392 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $38,921 |
| MounjaroTirzepatide | 24 | $37,560 |
| Nurtec OdtRimegepant Sulfate | 13 | $24,382 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $15,587 |
| NexlizetBempedoic Acid/Ezetimibe | 18 | $15,142 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $14,962 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $11,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $808 | $234,693155 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $268 | $179,541154 claims |
| Boehringer IngelheimJardiance | $346 | $146,45996 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $628 | $122,684118 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $697 | $102,90657 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $765 | $74,07661 claims |
| Johnson & JohnsonXarelto | $80 | $51,27750 claims |
| Esperion Therapeutics, Inc.Nexlizet | $134 | $15,14218 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $3,01831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lake Wales
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.